Showing 5031-5040 of 8223 results for "".
- New JAMA Dermatology Publication Features AID Accelerator Fund to Enable Progress of Promising Early-stage Scientific Technologieshttps://practicaldermatology.com/news/new-jama-dermatology-publication-features-aid-accelerator-fund-to-enable-progress-of-promisingearly-stage-scientific-technologies/2457810/A new article, "Catalyzing Future Drug, Device, and Information Technology Breakthroughs in Dermatology", in JAMA Dermatology features the Advancing Innovation in Dermatology (AID) Accelerator Fund. AID has created this mechanism to help enable and speed the product development
- Ortho Dermatologics' DUOBRII Improves Psoriasis Symptoms As Early As Two Weekshttps://practicaldermatology.com/news/ortho-dermatologics-duobrii-improves-psoriasis-symptoms/2457811/DUOBRII (halobetasol propionate and tazarotene) (IDP-118) lotion demonstrated significant superiority over vehicle as early as two weeks, according to new research in Journal of the American Academy of Dermatology</
- Take That, Kim and Kylie : Most Millennials Don't Want Your Advice on Cosmetic Surgeryhttps://practicaldermatology.com/news/take-that-kim-and-kylie/2457812/When it comes to deciding on nips and tucks, millennials are not inclined to trust social media or celebs, a new
- DefenAge® Skincare Trio Performs Well in New Studyhttps://practicaldermatology.com/news/defenage-skincare-trio-performs-well-in-new-study/2457818/Progenitor Biologics’ DefenAge® Skincare, a-three-step system “globally improves the visual appearance of aging skin without irritation, dryness, or inflammation,” according to new research in the
- American Academy of Dermatology Elects New Officers, Board Membershttps://practicaldermatology.com/news/american-academy-of-dermatology-elects-new-officers-board-members/2457825/The American Academy of Dermatology named its new officers and board members who will represent the more than 19,000 physicians who specialize in the diagnosis and medical, surgical and cosmetic treatment of skin, hair, and nail conditions. These officers and board members, all of whom are board-
- Proscia Inks Agreement to Bring Deep-Learning Technology to Dermatopathologyhttps://practicaldermatology.com/news/proscia-inks-agreement-to-bring-deep-learning-technology-to-dermatopathology/2457832/Proscia Inc., creators of AI-powered digital pathology software, signed a first-of-its-kind agreement with one of the largest dermatopathology labs in the country. This agreement provides Proscia with exclusive access to pathology slides and expert pathologist ground-truth data for an arr
- Botanical Dermatology Brand Kamedis Forms U.S. Medical Advisory Boardhttps://practicaldermatology.com/news/botanical-dermatology-brand-kamedis-forms-us-medical-advisory-board/2457834/Israeli-based Kamedis announced the formation of a U.S. medical advisory board. The members include: Zoe Draelos, MD, FAAD, a clinical and research dermatologist with a private solo practice in High Point, NC, who is also a Consulting Professo
- ALASTIN Adds to Board of Directorshttps://practicaldermatology.com/news/alastin-adds-to-board-of-directors/2457837/Ann Rhoads and Elisabeth Sandoval are now members of ALASTIN Skincare, Inc’s Board of Directors. Ms. Rhoads is a healthcare finance executive with more than 25 years of experience which includes roles as Chief Financial Officer of
- Colorescience Adds to Board of Directorshttps://practicaldermatology.com/news/colorescience-adds-to-board-of-directors/2457838/David Olsen and Ty Stiklorius are joining Colorescience’s Board of Directors. David Olsen is the Chief Executive Officer (CEO) of Cos Bar. Since joining Cos Bar in February 2016, he has worked to grow the company while
- First Patient Dosed in Proof-of-Concept Trial of Topical by Design JAK Inhibitor SNA-125 for Atopic Dermatitishttps://practicaldermatology.com/news/first-patient-dosed-in-proof-of-concept-trial-of-topical-by-design-jak-inhibitor-sna-125-for-atopic-dermatitis/2457839/The first patient has been dosed in Sienna Biopharmaceuticals, Inc.'s Phase 1/2 proof-of-concept clinical trial of topical product candidate SNA-125 in the treatment of atopic dermatitis and the associated pruritus. SNA-125 is designed to inhibit Janus kinase 3, or JAK3, and tropomyosin recep